These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9269715)

  • 1. Monoclonal anti-D for prophylaxis of RhD haemolytic disease of the newborn.
    Kumpel BM
    Transfus Clin Biol; 1997 Jul; 4(4):351-6. PubMed ID: 9269715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo studies of monoclonal anti-D and the mechanism of immune suppression.
    Kumpel BM
    Transfus Clin Biol; 2002 Jan; 9(1):9-14. PubMed ID: 11889904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal anti-D development programme.
    Kumpel BM
    Transpl Immunol; 2002 Aug; 10(2-3):199-204. PubMed ID: 12216950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma half-lives and bioavailability of human monoclonal Rh D antibodies BRAD-3 and BRAD-5 following intramuscular injection into Rh D-negative volunteers.
    Goodrick J; Kumpel B; Pamphilon D; Fraser I; Chapman G; Dawes B; Anstee D
    Clin Exp Immunol; 1994 Oct; 98(1):17-20. PubMed ID: 7923878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunization in Rh D- volunteers.
    Kumpel BM; Goodrick MJ; Pamphilon DH; Fraser ID; Poole GD; Morse C; Standen GR; Chapman GE; Thomas DP; Anstee DJ
    Blood; 1995 Sep; 86(5):1701-9. PubMed ID: 7655002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn.
    Brinc D; Lazarus AH
    Hematology Am Soc Hematol Educ Program; 2009; ():185-91. PubMed ID: 20008198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The introduction of human monoclonal anti-D for therapeutic use.
    Fletcher A; Thomson A
    Transfus Med Rev; 1995 Oct; 9(4):314-26. PubMed ID: 8541714
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro functional activity of IgG1 and IgG3 polyclonal and monoclonal anti-D.
    Kumpel BM
    Vox Sang; 1997; 72(1):45-51. PubMed ID: 9031501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn.
    Kumpel BM
    Clin Exp Immunol; 2008 Oct; 154(1):1-5. PubMed ID: 18727626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of Rh antibodies in haemolytic disease of the newborn.
    Hadley AG; Kumpel BM
    Baillieres Clin Haematol; 1993 Jun; 6(2):423-44. PubMed ID: 8043933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine monoclonal antibodies reactive with a human monoclonal anti-RhD antibody (BRAD-5).
    Walker RY; Andrew S; Kumpel BM; Austin EB
    Transfus Med; 2000 Sep; 10(3):225-31. PubMed ID: 10972918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fcgamma RIIIa (CD16).
    Kumpel BM; De Haas M; Koene HR; Van De Winkel JG; Goodrick MJ
    Clin Exp Immunol; 2003 Apr; 132(1):81-6. PubMed ID: 12653840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consensus conference on anti-D prophylaxis, April 7 & 8, 1997: final consensus statement. Royal College of Physicians of Edinburgh/Royal College of Obstetricians and Gynaecologists.
    Urbaniak SJ
    Transfusion; 1998 Jan; 38(1):97-9. PubMed ID: 9482402
    [No Abstract]   [Full Text] [Related]  

  • 14. Fetal RhD genotyping: a more efficient use of anti-D immunoglobulin.
    Daniels G; Finning K; Martin P; Summers J
    Transfus Clin Biol; 2007 Dec; 14(6):568-71. PubMed ID: 18436463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers.
    Kumpel BM
    Vox Sang; 2007 Aug; 93(2):99-111. PubMed ID: 17683353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal anti-D for immunoprophylaxis.
    Scott ML
    Vox Sang; 2001 Nov; 81(4):213-8. PubMed ID: 11903995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura.
    Stasi R
    Curr Opin Mol Ther; 2010 Dec; 12(6):734-40. PubMed ID: 21154165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of IgG anti-D bound to D-positive red cells infused into D-negative subjects after intramuscular injection of monoclonal anti-D.
    Kumpel BM; Judson PA
    Transfus Med; 1995 Jun; 5(2):105-12. PubMed ID: 7655572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adverse effects and patient information].
    Cortey A; Brossard Y
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S112-1S118. PubMed ID: 16495836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing rhesus D haemolytic disease of the newborn by giving anti-D immunoglobulin: are the guidelines being adequately followed?
    Harding K
    Br J Obstet Gynaecol; 1997 Jul; 104(7):869-70. PubMed ID: 9236664
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.